Members
| Location: | South San Francisco, California |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.gene.com |
| Contact: |
Steve Krognes 1 650 2251000 |
| Description: | Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 35 years, using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, Genentech is among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. In March 2009, Genentech became a member of the Roche Group. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development (gRED) operates as an independent center within Roche. Genentech Partnering supports Genentech Research and Early Development and is composed of the Business Development and Alliance Management groups that supported Genentech prior to the merger. Developing alliances has been one of Genentech's key strategies for success from its inception. Several marketed products and products in clinical development have arisen from successful collaborations. Genentech considers collaborations wherever there is excellent science and the potential for a good strategic fit. Genentech is dedicated to bringing considerable resources to the alliance, and is open to different collaboration structures. On behalf of Genentech Research and Early Development, Genentech Business Development welcomes opportunities to collaborate on discoveries in the following areas, at any stage of development between research and clinical proof-of-concept (typically completion of phase II studies): Oncology, Immunology, Neuroscience, Ophthalmic Diseases, Microbial Pathogenesis, Metabolism and Acute Cardiovascular Disorders. Genentech Business Development also seeks to identify novel platforms for antibody and small molecule lead generation and optimization, as well as technologies for biomarker assays and companion diagnostic development. |
| Location: | Quebec, Quebec |
|---|---|
| Industry Sector: | Biotechnology / R&D Services |
| Contact: |
Michel G. Bergeron (michel.g.bergeron@crchul.ulaval.ca) 1 418 6542705 |
| Description: | GenePOC is a start-up of the Centre de recherche en infectiologie (CRI) of Université Laval in Québec City. GenePOC was created to undertake technology transfer of CRI’s most recent rapid automated Genomics Point-of-Care tests (GPOCTs). |
| Location: | Ottawa, Ontario |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations / Medical Facilities |
| Website: | www.genomecanada.ca |
| Contact: |
Cindy Bell (info@genomecanada.ca) 1 613 7514460 |
| Description: | Genome Canada adheres to an innovative business model which is based on the premise of funding and managing large-scale multi-disciplinary internationally peer-reviewed research projects and of providing access to cutting-edge science and technology platforms to researchers in all genomics and proteomics fields of expertise. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.genzyme.ca |
| Contact: |
Peter Brenders (Canadageneralquestions@genzyme.com) 1 905 625 0011 |
| Ownership: | Subsidiary - New York Stock Exchange (NYSE): SNY |
| Description: | Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. They accomplish their goals through world-class research, collaboration with the global patient community, and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, they are dedicated to making a positive impact on the lives of the patients and families they serve. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represent groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.gilead.com |
| Contact: |
Susan Hubbard (public_affairs@gilead.com) 1 905 363 8008 |
| Ownership: | Subsidiary - NASDAQ: GILD |
| Description: | Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need. Gilead Sciences Ontario, provides medical, regulatory, marketing and sales support for Truvada®, Viread®, and Hepsera® in Canada. |
| Location: | Ottawa, Ontario |
|---|---|
| Industry Sector: | Professional Services and Consulting |
| Website: | www.globalpublicaffairs.ca |
| Contact: |
Genevieve Young (gyoung@globalpublic.com) 1 613 7822336 |
| Description: | Global Public Affairs is Canada’s premiere public policy and government relations firm. The company provides its Canadian and international clients with strategic research and counsel, government advocacy and issues management. |
| Location: | Oakville, Ontario |
|---|---|
| Industry Sector: | Supplier & Engineering |
| Website: | www.patientdirect.ca |
| Contact: |
Steve Duffield (starantino@gmdpharma.ca) 1 905 827 1300 |
| Description: | GMD PharmaSolutions provides supply chain services to the life science and pharmaceutical industries in Canada. The company’s Good Manufacturing Practice facility in Oakville, Ont. offers pharmaceutical companies with distribution support across a wide range of products including pharmaceuticals, biological products, bulk API, natural health products, controlled substances, medical devices, cells, tissues and organs, providing a complete solution to the life sciences industry in the Canadian market. The company currently serves about 30 clients, with half of the distribution focusing on biological products and the remainder on the distribution of generic products, giving the generic manufacturers the unique opportunity to create a direct distribution through GMD PharmaSolutions. |
| Location: | Ottawa, Ontario |
|---|---|
| Industry Sector: | Professional Services and Consulting |
| Website: | www.gowlings.com |
| Contact: |
Rhowan Sivel (info@gowlings.com) 1 613 233 1781 |
| Description: | Gowlings provides strategic counsel to life sciences and pharmaceutical clients for all their legal needs. As a full service firm of more than 750 professionals, they offer decades of experience in this industry to help clients protect, maintain, enforce and defend industry innovations. Their life sciences practice has been ranked as “Highly Recommended” by PLC Which Lawyer? 2011 and as Tier-1 for life science patent litigation (Canada) by Intellectual Asset Magazine. They are also ranked among the top four law firms for Canadian M&A by Thomson Reuters. For the last 15 years consecutively, Gowlings has been ranked a Tier-1 leader in trade-mark, copyright and patent law by Managing Intellectual Property (MIP), World IP Survey. In addition, Gowlings is counsel of record in more patent infringement actions, more trade-mark proceedings and more Patented Medicine Prices Review Board (PMPRB) appearances than any other Canadian firm and was ranked first among ALL Canadian firms for PCT applications filed (MIP, 2010 PCT Survey). They can help with IP protection (patent, trade-mark, domain name, copyright, data protection, trade secret and advertising law); litigation, including product liability/class action litigation, patent litigation including PM(NOC) proceedings and PMPRB pricing litigation; and business law issues (corporate finance, M&A, tax, transfer pricing and commercialization). As a global law firm, we have offices in Montréal, Ottawa, Toronto, Hamilton, Waterloo Region, Calgary, Vancouver, Moscow, London and Beijing. The Firm provides legal services in Canada, the U.K., and Russia and the CIS through the entities Gowling Lafleur Henderson LLP, Gowling Lafleur Henderson S.E.N.C.R.L.., s.r.l., Gowlings (UK) Inc., and Gowlings International Inc. In 2011, the Firm opened the Gowlings International Inc. Beijing Representative Office. Combining traditional legal services with innovative solutions in a number of highly specialized areas of IP, business and advocacy law, Gowlings is the life sciences and pharmaceutical go-to law firm. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.grifols.com |
| Contact: |
Drayton Virkler (drayton.virkler@talecris.com) 1 905 6145575 |
| Ownership: | Subsidiary - NASDAQ: TLCR |
| Description: | Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas. |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Investor |
| Website: | www.growthworks.ca |
| Contact: |
Joseph Regan (info@growthworks.ca) 1 416 9347731 |
| Description: | GrowthWorks is a venture capital management company. They specialize in the management and growth of regionally based venture capital funds (RVCs) and has assets under management of approximately $525 million. |
